University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

heXem bio Inc.

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

ImmunologyOncology

Funding Stage

Seed

Founders

Gabriel Levesque TremblayMo EbrahimkhaniSamira KianiJoshua HislopSamet Yildirim

Website

https://hexemb.io/
heXem bio Inc.

heXem bio is developing therapies designed to restore the function of aging blood-forming stem cells. Its approach recreates a supportive early-development environment outside the body, aiming to rejuvenate the cells that replenish blood and immune systems. The initial program targets better bone marrow transplant outcomes for patients with blood cancer. [1]

The company's scientific foundation includes technology licensed from the University of Pittsburgh, connecting developmental biology with the pursuit of healthier aging. In 2026, heXem bio announced a $10.4 million seed round led by Draper Associates to advance its blood stem cell rejuvenation platform. [2] [3]

Discover More with AI